NCT02706405 - JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 15, 2016

Primary Completion Date

May 28, 2021

Study Completion Date

May 28, 2021

Conditions

Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Diffuse Large B-Cell LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 RearrangementsRefractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma

Interventions

BIOLOGICAL

Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014

Given IV

DRUG

Cyclophosphamide

Given IV

BIOLOGICAL

Durvalumab

Given IV

DRUG

Fludarabine

Given IV

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle